Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Johannes F.E. Mann(München Klinik Schwabing), Roland E. Schmieder(Friedrich-Alexander-Universität Erlangen-Nürnberg), Matthew McQueen(Population Health Research Institute), Leanne Dyal(Population Health Research Institute), Helmut Schumacher(Boehringer Ingelheim (Germany)), Janice Pogue(Population Health Research Institute), Xingyu Wang(Fu Wai Hospital), Aldo P. Maggioni(Associazione Nazionale Medici Cardiologi Ospedalieri), Andrzej Budaj(Grochowski Hospital), S Chaithiraphan(Bangkok Hospital), Kenneth Dickstein(Stavanger University Hospital), Mátyás Keltai(Gottsegen National Cardiovascular Center), Kaj Metsärinne(Turku University Hospital), Ali Oto(Hacettepe University), Alexander Parkhomenko, Leopoldo Soares Piegas(Instituto Dante Pazzanese de Cardiologia), Tage Lysbo Svendsen(Holbæk Sygehus), Koon Teo(McMaster University), Salim Yusuf(McMaster University)
The Lancet
August 1, 2008
Cited by 1,587

Abstract


Related Papers

No related papers found

Powered by citation graph analysis